Page last updated: 2024-08-26

mci 9038 and Behavior Disorders

mci 9038 has been researched along with Behavior Disorders in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Fewel, ME; Hoff, JT; Hua, Y; Keep, RF; Muraszko, KM; Schallert, T; Tang, LL; Xi, GH	1

Other Studies

1 other study(ies) available for mci 9038 and Behavior Disorders

Article	Year
Systemic use of argatroban reduces tumor mass, attenuates neurological deficits and prolongs survival time in rat glioma models. Acta neurochirurgica. Supplement, 2005, Volume: 95 Topics: Animals; Anticoagulants; Antineoplastic Agents; Arginine; Brain; Brain Edema; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Glioma; Injections, Intraventricular; Male; Mental Disorders; Pipecolic Acids; Rats; Rats, Inbred F344; Sulfonamides; Survival Rate; Treatment Outcome	2005

Article

Year

Systemic use of argatroban reduces tumor mass, attenuates neurological deficits and prolongs survival time in rat glioma models.

Acta neurochirurgica. Supplement, 2005, Volume: 95

Topics: Animals; Anticoagulants; Antineoplastic Agents; Arginine; Brain; Brain Edema; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Glioma; Injections, Intraventricular; Male; Mental Disorders; Pipecolic Acids; Rats; Rats, Inbred F344; Sulfonamides; Survival Rate; Treatment Outcome

2005